These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22033113)

  • 1. Defining and predicting indolent and low risk prostate cancer.
    Bangma CH; Roobol MJ
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):235-41. PubMed ID: 22033113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive models in diagnosing indolent cancer.
    Bangma CH; Roobol MJ; Steyerberg EW
    Cancer; 2009 Jul; 115(13 Suppl):3100-6. PubMed ID: 19544551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overdiagnosis and overtreatment of early detected prostate cancer.
    Bangma CH; Roemeling S; Schröder FH
    World J Urol; 2007 Mar; 25(1):3-9. PubMed ID: 17364211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contemporary concept of significant versus insignificant prostate cancer.
    Ploussard G; Epstein JI; Montironi R; Carroll PR; Wirth M; Grimm MO; Bjartell AS; Montorsi F; Freedland SJ; Erbersdobler A; van der Kwast TH
    Eur Urol; 2011 Aug; 60(2):291-303. PubMed ID: 21601982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should prostate-specific antigen screening be offered to asymptomatic men?
    van Vugt HA; Bangma CH; Roobol MJ
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations.
    Roemeling S; Roobol MJ; Kattan MW; van der Kwast TH; Steyerberg EW; Schröder FH
    Cancer; 2007 Nov; 110(10):2218-21. PubMed ID: 17893906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
    Dong F; Kattan MW; Steyerberg EW; Jones JS; Stephenson AJ; Schröder FH; Klein EA
    J Urol; 2008 Jul; 180(1):150-4; discussion 154. PubMed ID: 18485398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updating the prostate cancer risk indicator for contemporary biopsy schemes.
    Bul M; Delongchamps NB; Steyerberg EW; de la Roza G; van Leeuwen PJ; Zhu X; van Vugt HA; Haas GP; Schröder FH; Roobol MJ
    Can J Urol; 2011 Apr; 18(2):5625-9. PubMed ID: 21504651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients.
    Suzuki H; Komiya A; Kamiya N; Imamoto T; Kawamura K; Miura J; Suzuki N; Nakatsu H; Hata A; Ichikawa T
    Urology; 2006 Jan; 67(1):131-6. PubMed ID: 16413348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
    Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Loblaw A; Pond GR; Emami M; Sugar L; Sweet J; Narod SA
    Can J Urol; 2006 Apr; 13 Suppl 2():2-10. PubMed ID: 16672122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
    Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
    Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer: epidemiology and health-related quality of life.
    Penson DF; Rossignol M; Sartor AO; Scardino PT; Abenhaim LL
    Urology; 2008 Dec; 72(6 Suppl):S3-11. PubMed ID: 19095126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
    van Leeuwen PJ; van den Bergh RC; Wolters T; Zhu X; Bul M; Schröder FH; Bangma CH; Roobol MJ
    Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
    Steyerberg EW; Roobol MJ; Kattan MW; van der Kwast TH; de Koning HJ; Schröder FH
    J Urol; 2007 Jan; 177(1):107-12; discussion 112. PubMed ID: 17162015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH; Roobol MJ
    Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT
    J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging low-risk prostate cancer.
    Shukla-Dave A; Hricak H; Scardino PT
    Curr Opin Urol; 2008 Jan; 18(1):78-86. PubMed ID: 18090495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.